The effect of ARBs and ACEIs on lung levels of ACE2 has been controversial, which became particularly relevant for patients vulnerable to severe COVID-19, such as aged patients and patients with obesity, hypertension, or diabetes taking these drugs. The gene discussed is ACE2; the disease is COVID-19.